Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1094
http://purl.obolibrary.org/obo/NCIT_C1094
|
|---|---|
| Preferred Name | Fludarabine |
| Definitions |
A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. (NCI04) |
|---|---|
| prefLabel | Fludarabine
|
| label | Fludarabine
|
| code | C1094
|
| prefixIRI | NCIT:C1094
|
| in_subset |
See more
See less
|
| Preferred_Name | Fludarabine
|
| FDA_UNII_Code | P2K93U8740
|
| Is_PCDC_AML_Permissible_Value_For_Variable | |
| Contributing_Source |
FDA
PCDC
|
| Chemical_Formula | C10H12FN5O4
|
| Maps_To | Fludarabine
|
| CAS_Registry | 21679-14-1
|
| NSC Number | 118218
|
| Legacy Concept Name | Fludarabine
|
| type | |
| ALT_DEFINITION | The active ingredient in a drug used to treat B-cell chronic lymphocytic leukemia (CLL) that has not responded to treatment with other anticancer drugs or that has gotten worse. Fludarabine blocks cells from making DNA and may kill cancer cells. It is a type of purine antagonist and a type of ribonucleotide reductase inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Accepted_Therapeutic_Use_For | Acute nonlymphocytic leukemia; Chronic lymphocytic leukemia; Indolent Non - Hodkins Lymphoma
|
| Semantic_Type |
Pharmacologic Substance
Nucleic Acid, Nucleoside, or Nucleotide
|
| UMLS_CUI | C0059985
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |